© Reuters. FILE PHOTO: Sanofi logo at the company’s headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier
PARIS (Reuters) -French healthcare group Sanofi (NASDAQ:), which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion).
“This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023,” Sanofi said in a statement.
This month, analysts at investment bank JP Morgan had said they expected Sanofi to raise its peak sales guidance for Dupixent to about $15 billion.
Sanofi is working with British partner GlaxoSmithKline (NYSE:) to develop a COVID-19 vaccine.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences (NASDAQ:) in the field of treatments for oncology, immunology and inflammation.
($1=0.9096 euros)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
